Neurogene, a trailblazer in the gene therapy field concentrating on rare neurological diseases, has successfully clinched $200 million through a private funding deal designed to extend its financial runway until late 2027. This financing structure, recognized as a PIPE financing (Private Investment
Roche is considering seeking accelerated approval for its experimental Alzheimer’s drug, trontinemab, following promising early results. Trontinemab is currently in Phase 2 testing and has shown significant potential in reducing amyloid levels in the brain. This approach has been previously
Novo Nordisk recently announced its intention to seek regulatory approval for the use of semaglutide, the active ingredient in its profitable weight loss drug, for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). This decision came after a Phase 3 clinical trial yielded
In a significant development, Monte Rosa Therapeutics, a biotechnology company based in Boston, has finalized a highly lucrative global exclusive development and commercialization license agreement with Novartis valued at up to $2.1 billion on October 28, 2024. Monte Rosa Therapeutics is focused on
LakeShore Biopharma Co., Ltd (NASDAQ: LSB), a prominent biopharmaceutical company, has successfully regained compliance with Nasdaq's minimum bid price requirement after experiencing non-compliance due to a prolonged period of its share price falling below $1.00. As of October 21, 2024, the company
Artificial Intelligence (AI) has the potential to revolutionize drug discovery and development, offering numerous advantages that could transform current practices in the biopharmaceutical industry. By merging Accenture's advanced capabilities in AI scaling with the innovative ITO™ platform
